Aegerion gets US subpoena on rare-disease drug marketing


This is a summary. To read the whole story subscribe to

Aegerion Pharmaceuticals Inc., maker of the drug Juxtapid for a rare cholesterol disorder, has received a subpoena from the US Department of Justice for documents on its marketing and sale of the medicine. The Cambridge company said it intends to cooperate with the inquiry, and that it ‘‘is committed to complying with all applicable laws, rules and regulations.’’ CEO Marc Beer received a warning letter from the FDA in November about comments in a CNBC interview. The FDA said Beer’s statements ‘‘provide evidence that Juxtapid is intended for new uses, for which it lacks approval.’’ It doesn’t know if the inquiry is related to the letter.

Full story for subscribers.

Get the full story with unlimited access to

Just 99 cents for four weeks.